Focus on Infectious Disease

Resistance to antimicrobials is a serious and growing problem in the treatment of infectious diseases.

In fact, for some bacterial pathogens, since there are no good antibiotic options, we are effectively returning to the pre-antibiotic era in the treatment of infections. This is happening at a time when there has been an explosion of new information about the basic biology of pathogens and how a host responds to infection. We're using this information to develop medicines and technologies that combat serious bacterial and viral infections.

At Genentech we're focused on exploring new antibacterial targets, antiviral targets and new mechanisms for killing pathogens, as well as new ways to deliver therapeutics to the site of infection that are both more efficient at pathogen elimination and less toxic to the host. In addition, our research efforts are focused on ways of combatting resistance mechanisms to existing drugs.

Key Publications

Nature, November 2015
Novel antibody–antibiotic conjugate eliminates intracellular S. aureus
Proceedings of the National Academy of Sciences, June 2014
Mechanism for neutralizing activity by the anti-CMV gH/gL monoclonal antibody MSL-109
The Journal of Infectious Diseases, April 2014
Global gene expression of methicillin-resistant Staphylococcus aureus USA300 during human and mouse infection
PLOS Pathogens, October 2013
Novel Staphylococcal Glycosyltransferases SdgA and SdgB Mediate Immunogenicity and Protection of Virulence-Associated Cell Wall Proteins
Cell Host & Microbe, July 2013
An In Vivo Human-Plasmablast Enrichment Technique Allows Rapid Identification of Therapeutic Influenza A Antibodies
Journal of Molecular Biology, June 2013
Glycan Shifting on Hepatitis C Virus (HCV) E2 Glycoprotein Is a Mechanism for Escape from Broadly Neutralizing Antibodies